Search Results - "ExteNET Study Group"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    Authors: Chan A Moy B Mansi J et al.

    Corporate Authors: Chan A Moy B Mansi J et al.

    Source: Clinical breast cancer [Clin Breast Cancer] 2021 Feb; Vol. 21 (1), pp. 80-91.e7. Date of Electronic Publication: 2020 Oct 06.

    Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

    PDF Full Text
    Save to List
  2. 2

    Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

    Authors: Holmes FA Moy B Delaloge S et al.

    Corporate Authors: Holmes FA Moy B Delaloge S et al.

    Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 May; Vol. 184, pp. 48-59. Date of Electronic Publication: 2023 Feb 10.

    Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

    Save to List
  3. 3

    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

    Authors: Martin M Holmes FA Ejlertsen B et al.

    Corporate Authors: Martin M Holmes FA Ejlertsen B et al.

    Source: The Lancet. Oncology [Lancet Oncol] 2017 Dec; Vol. 18 (12), pp. 1688-1700. Date of Electronic Publication: 2017 Nov 13.

    Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

    Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

    Save to List
  4. 4

    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Authors: Chan A Delaloge S Holmes FA et al.

    Corporate Authors: Chan A Delaloge S Holmes FA et al.

    Source: The Lancet. Oncology [Lancet Oncol] 2016 Mar; Vol. 17 (3), pp. 367-377. Date of Electronic Publication: 2016 Feb 10.

    Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

    Save to List

Search Tools: